EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.
about
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.EMT- and MET-related processes in nonepithelial tumors: importance for disease progression, prognosis, and therapeutic opportunities.Recapitulating in vivo-like plasticity of glioma cell invasion along blood vessels and in astrocyte-rich stroma.Nuclear galectin-1-FOXP3 interaction dampens the tumor-suppressive properties of FOXP3 in breast cancer.The role of tumor microenvironment in resistance to anti-angiogenic therapy.LDH-Apromotes epithelial-mesenchymal transition by upregulating ZEB2 in intestinal-type gastric cancer.
P2860
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.
@en
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.
@nl
type
label
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.
@en
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.
@nl
prefLabel
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.
@en
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.
@nl
P2093
P2860
P50
P356
P1476
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.
@en
P2093
A Acker-Palmer
B K Garvalov
F Finkelmeier
G Reifenberger
H Zum Buttel
M R Aburto
P2860
P2888
P356
10.1038/NCOMMS12329
P407
P577
2016-07-29T00:00:00Z
P6179
1001336984